Find an expert

I am a medicinal chemist and postdoctoral research fellow at the University of Queensland, Australia, where I obtained my BSc (Hons) with a major in organic chemistry in 2011. Following this, I worked at the Institute for Future Environments and later the Centre for Tropical Crops and Biocommodities at QUT, where I gained experience in analytical chemistry, as well as molecular biology and genetics. In 2015, I returned to UQ to begin my PhD in the design and synthesis of novel antifungals targeting invasive infection under the supervision of Prof. Craig Williams and Prof. Luke Guddat, which I completed in 2019. My combined experience in synthetic chemistry - particularly in the synthesis of heterocyclic small molecules - and molecular biology has since led to my current position at UQ under the supervision of Prof. Avril Robertson, where my focus is once again on the design and synthesis of novel antifungals. Broadly, my research interests lie in the pursuit of drug design and development campaigns addressing difficult or under-researched clinical concerns, and in particular, the use of novel bioisosteric approaches to improve drugability and drug efficacy.

More recently, I have developed an interest in Australian mushroom species. Very little recorded knowledge on our endemic mushrooms species exists. My research in this space seeks to characterise the genetic and molecular features of Australian wood rot mushrooms, which are critical players in maintaining and restoring the health of our unique forests ecosystems. With this information we aim to better understand our fungal biodiversity and the ecological roles they play, and to explore their potential uses in several industries. We are also investigating the biological activity of extracts and molecules derived from these mushrooms against models of human diseases, such as Alzheimer's, cancer, and drug-resistant microbial infections.

Prof David Ascher is currently an NHMRC Investigator and Director of the Biotechnology Program at the University of Queensland. He is also Head of Computational Biology and Clinical Informatics at the Baker Institute.

David’s research focus is in modelling biological data to gain insight into fundamental biological processes. One of his primary research interests has been developing tools to unravel the link between genotype and phenotype, using computational and experimental approaches to understand the effects of mutations on protein structure and function. His group has developed a platform of over 40 widely used programs for assessing the molecular consequences of coding variants (>7 million hits/year).

Working with clinical collaborators in Australia, Brazil and UK, these methods have been translated into the clinic to guide the diagnosis, management and treatment of a number of hereditary diseases, rare cancers and drug resistant infections.

David has a B.Biotech from the University of Adelaide, majoring in Biochemistry, Biotechnology and Pharmacology and Toxicology; and a B.Sci(Hon) from the University of Queensland, majoring in Biochemistry, where he worked with Luke Guddat and Ron Duggleby on the structural and functional characterization of enzymes in the branched-chain amino acid biosynthetic pathway. David then went to St Vincent’s Institute of Medical Research to undertake a PhD at the University of Melbourne in Biochemistry. There he worked under the supervision of Michael Parker using computational, biochemical and structural tools to develop small molecules drugs to improve memory.

In 2013 David went to the University of Cambridge to work with Sir Tom Blundell on using fragment based drug development techniques to target protein-protein interactions; and subsequently on the structural characterisation of proteins involved in non-homologous DNA repair. He returned to Cambridge in 2014 to establish a research platform to characterise the molecular effects of mutations on protein structure and function- using this information to gain insight into the link between genetic changes and phenotypes. He was subsequently recruited as a lab head in the Department of Biochemistry and Molecular Biology at the University of Melbourne in 2016, before joining the Baker Institute in 2019 and the University of Queensland in 2021.

He is an Associate Editor of PBMB and Fronteirs in Bioinformatics, and holds honorary positions at Bio21 Institute, Cambridge University, FIOCRUZ, and the Tuscany University Network.

Professor Antje Blumenthal combines her expertise in immunology and microbiology to lead research on molecular mechanisms that control immune responses to infection, alongside more recently developed research on new antimicrobials. The overall goal of her research is to improve our ability to treat severe bacterial infections as part of the global efforts to overcome the threat posed by antibiotic-resistant bacteria. Prof Blumenthal graduated with a major in Microbiology from the Christian-Albrechts-University in Kiel, Germany, pursued PhD research in Immunology at the Leibniz Research Center for Medicine and Biosciences Borstel, Germany, and undertook postdoctoral training at Weill Cornell Medical College, New York, USA. She joined The University of Queensland Diamantina Institute in 2010 where she leads the Infection & Inflammation Group, fostering cross-disciplinary collaborations with immunologists, microbiologists, chemists, clinical research teams and industry partners. Her research is enabled by major funding from international and national agencies, and has been recognised internationally and nationally by prestigious awards, speaking invitations at eminent conferences and institutions, invitations to peer-review for esteemed journals and funding agencies. Prof Blumenthal is an enthusiastic undergraduate teacher and research student advisor. She is proactive in advancing the careers of junior scientists, leads the development and implementation of initiatives that promote equity, diversity and inclusion in science, and a positive workplace culture. Through leadership roles within the University and professional societies as well as editorial roles for international journals, Prof Blumenthal actively contributes to the scientific community.

Mikael Bodén has a PhD in Computer Science and statistical machine learning from the University of Exeter (UK) but has spent the last decade and a half in biological research environments, including the Institute for Molecular Bioscience/ARC Centre of Excellence in Bioinformatics and the School of Chemistry and Molecular Biosciences, where he is currently located. He is the director of UQ’s postgraduate program in bioinformatics. Mikael Bodén has supervised 7 postdocs from funding he received from both ARC and NHMRC; he has been the primary advisor for 11 PhD and 3 MPhil graduates; he is currently supervising another 6 PhD students in bioinformatics and computational biology. Mikael Bodén collaborates with researchers in neuroscience, developmental biology, protein engineering and bioeconomy to mention but a few, and contributes expertise in the processing, analysis and integration of biological data; this is exemplified by recent publications in Science, Nature Catalysis, Nature Communications, Cell Systems, Nucleic Acids Research and Bioinformatics.

Dr Andrew Brooks is the Group Leader of the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute (UQ DI) within the Translational Research Institute. Andrew completed his Honours research on Flaviviruses in 1996 at the Department of Microbiology and Immunology at James Cook University and then moved to the Department of Biochemistry to study Dengue Virus where he completed his PhD in 2002. He then moved to St Jude Children’s Research Hospital in Memphis, TN, USA where he researched the role of Epstein-Barr Virus in B-cell lymphomagenesis. He then joined the research group headed by Prof Michael Waters at the Institute for Molecular Bioscience, UQ in 2006 and subsequently began his independent research group at UQ DI in 2014. Andrew’s research interests are in cytokine receptors, cell signalling, oncogenesis, and immunology. His current research focus is on the molecular mechanisms of class I cytokine receptor activation including the growth hormone receptor (GHR), thrombopoietin receptor (TpoR/MPL), IL-7 receptor, and IL-6 receptor (IL-6R). In addition, he is investigating the regulation of inflammation by HLA-G. His research has led to publications in journals including Science, Blood, Hepatology, Oncogene, Nature Cell Biology, and PNAS. He has been the secured of over $12 million in research and commercialisation funding from sources including NHMRC, ARC, Innovation Connections, and Merck. He has a number of national and international collaborations, a scientific founder of a start-up company, and is an Editorial Board member for the Journal Cancers and Human Cell. He was previously a committee member of Australian Early-Mid Career Researchers Forum (AEMCRF) launched by the Australian Academy of Science.

Dr Seth Cheetham is an ARC Discovery Early Career Award Fellow and group leader at the Australian Institute for Bioengineering and Nanotechnology. He is also the Deputy Director of the BASE facility, Australia's leading mRNA manufacturing hub. He completed his PhD at the University of Cambridge, supported by the Herchel Smith Research Studentship. Seth is a molecular biologist and geneticist with a focus on mRNA drugs, synthetic biology and epigenetics. He has authored 22 publications, including twelve as a first author and four as a corresponding author. He has published in some of the most influential molecular biology journals including Science, Molecular Cell, Nature Reviews Genetics , Genome Biology and Nature Structural and Molecular Biology. His work has attracted > $10M in funding from an ARC DECRA (2022), NHMRC Fellowship (2019), MRFF grants, UQ HERA Grant, a Cancer Australia Grant (2021), Mater Foundation seeding grant (2019), a UQ ECR grant (2019) and the UQ Genome Innovation Hub (2020). In 2021 Seth was awarded the Genetics Society of Australasia Alan Wilton ECR awarded for his research in the field of RNA and epigenetics.

I am a Senior Research Fellow, NHMRC Emerging Leader Fellow, and Group Leader at UQ Frazer Institute. I was awarded my PhD in late 2017 by Biomedicine Discovery Institute, Monash University. Under the UQ Health Research Accelerator (HERA) program, I lead a team to investigate T and B cell responses that profoundly regulate vaccine responses, viral clearance, and anti-tumour immunity.

My research program employs combinatorial methodologies of Biochemistry and Immunology to uncover new molecular mechanisms controlling T-cell-mediated immunity:

1. The action of T cells is required in antibody responses for suppressing viral infection or tumour growth and to confer protection upon vaccination. In particular, follicular helper T (Tfh) cells, a specialised subset of CD4+ T cells, essentially instruct the B cells to produce long-lived antibody protection. The knowledge of Tfh cells has fundamentally enabled vaccine development and therapy design for autoimmune diseases.

2. T-cell-derived cytokines play pivotal roles in both humoral and cellular immunity. Particularly, interleukin-21 (IL-21) is essential for supporting germinal centre (GC) reaction, where the B cell memory and long-lived antibody responses are generated. Besides, IL-21 is also the only known cytokine to maintain the functionalities of CD8+ T cells in the context of chronic infections or cancers by preventing a loss-of-function program termed 'exhaustion'.

This research program has generated multiple cutting-edge discoveries in the field, producing publications as 1st or joint 1st authors in top-tier journals including Nature Immunology, Science Immunology, and Nature Communications.

Paul Clarke is Director of the Frazer Institute, a leading translational medical research centre studying cancer, autoimmune diseases, infection and immunity, and the genetic basis of disease. Professor Clarke became Director in 2017 and was previously Associate Dean (Research) in Medicine at the University of Dundee in Scotland, Senior Research Fellow at the University of Manchester in England, and Research Fellow at the European Molecular Biology Laboratory in Heidelberg, Germany. Professor Clarke studied Biochemistry at the University of Bristol and undertook research for his PhD at the University of Dundee.

Frazer Institute, formerly UQ Diamantina Institute, is named in honour of its Founding Director, Emeritus Professor Ian Frazer, co-discoverer of the Gardasil HPV cervical cancer vaccine. Frazer Institute is part of The University of Queensland Faculty of Medicine and is a key partner in the Translational Research Institute, a $360 million research facility at the Princess Alexandra Hospital precinct in Woolloongabba. Scientists and clinical researchers at Frazer Institute develop new methods for the prevention, detection and treatment of human diseases.

During my postgraduate studies and postdoctoral fellowship, I gained experience in a wide range of chemical biology techniques as well as in initiating and managing collaborations. Building on a background in chemistry and biochemistry, I developed my skills in peptide chemistry and NMR spectroscopy during my PhD in Australia, synthesizing a variety of disulfide-rich cyclic peptides and elucidating their structures and dynamics by NMR spectroscopy. I have gained further experience in protein chemistry, solid phase peptide synthesis and protein ligations during my postdoctoral fellowship in Vienna, collaborating with Syntab Therapeutics on a project involving synthesis and development of synthetic antibodies for cancer therapy. I have recently taken up a UQ Development Fellowship to establish my independent research area in synthesis and structural biology of posttranslationally modified proteins.

Professor Simon Cool is Professor of Bioengineering and Director of the UQ Advanced Cell Therapy Manufacturing Initiative in the School of Chemical Engineering at the University of Queensland.

Professor Cool began his scientific career at the University of Queensland more than 20 years ago. He received his BSc (hons) and PhD degrees from the University of Queensland, where he subsequently held a faculty position in the School of Biomedical Sciences. His areas of studies have included age-related changes in the structure of bone and teeth and the extracellular matrix compartment of skeletal tissue that guide stem cell behaviour and wound repair. Professor Cool was invited to join the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore in 2003 as a Principal Investigator. He then joined A*STAR’s Institute of Medical Biology (IMB) in 2008, shortly after its inception, to further his research in regenerative medicine, serving as Senior Principal Investigator of the Glycotherapeutics Group. In October 2020, Professor Cool re-joined the Institute of Molecular and Cell Biology (IMCB) as a Research Director, Glycotherapeutics, where he focused on developing novel glycosaminoglycan biomolecules that enhance wound repair and control adult human mesenchymal stem cell activity.

Professor Cool has 117 patent applications across 26 families with 51 granted in the fields of glycosaminoglycan biochemistry, regenerative medicine and stem cell science. He has more than 150 publications and continues to foster strong strategic collaborations both nationally and internationally with academic and industry groups. He has a strong biomanufacturing and translational focus with experience in taking glycosaminoglycan-based devices through discovery RnD on to pre-clinical and clinical testing. Professor Cool also has an entrepreneurial and licensing background having successfully spun-off some of his technology to a US-based regenerative medicine start-up company, SMC Biotechnology Ltd. Professor Cool holds a Visiting Professor appointment at the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore and an Adjunct Professor (Research) appointment in the Orthopaedic Department at the National University of Singapore (NUS). Prior to his move back to UQ, he previously held the position of Treasurer, Tissue Engineering and Regenerative Medicine International Society, Asia Pacific Chapter (TERMIS-AP) and Treasurer, Stem Cell Society Singapore (SCSS). He also held senior leadership positions in several Singapore-based R&D programmes, notably as Director, Allogeneic Stem Cell Manufacturing (ASTEM) and Theme Leader in Advanced Manufacturing for Biological Materials (AMBM). Prof Cool currently serves on the Editorial Board of the journals Biomaterials, Tissue Engineering and Regenerative Medicine, and is Asia-Pacific Regional Editor for Stem Cells and Development.

I was awarded my PhD in Computational Biophysics from the University of Western Australia (2012) for my work on combining molecular modelling and simulation approaches with fluorescence spectroscopy experiments to study mechanosensitive ion channels.

Following this, I carried out Postdoctoral work at the University of Queensland and Curtin University, funded by Early Career Fellowships from the Swiss National Science Foundation and the Australian National Health and Research Council (NHMRC). In 2019, I joined UTS under a UTS Chancellor's Postdoctoral Research Fellowship and started my independent research group. In 2021, I returned to the University of Queensland as a Senior Lecturer.

Apart from my research, I am a passionate advocate for mental health in academia and

supporting PhD students. My teaching and supervision are guided by encouraging students to become 'critical thinkers'. I practice mindful leadership and aim to integrate kindness and gratitude into how I lead my research team.

Pratap is an IP Strategist and Patent researcher. He has expertise in dealing with Intellectual Property issues in relation to emerging technologies such as Artificial Intelligence (AI), 3D bioprinting and synthetic biology. He is currently a Postdoctoral fellow at TC Bernie School of Law, University of Queensland, Australia. Pratap pursued his PhD from the Centre for Law and Genetics, University of Tasmania, Australia where his research was focused on "Patenting issues related to Bioprinted tissues and Bioinks." In 2018, he was invited by Govt. of Japan to assist the Japanese Patent Office (JPO) in harmonizing Japanese Patent Law in relation to AI. In 2017, he completed his Master of Law (LLM) in Intellectual Property from the World Intellectual Property Organization (WIPO), Geneva and the Queensland University of Technology, Australia. He is the recipient of the prestigious International Fellowship offered by WIPO. He holds a Master's degree in Genomics from the Central University of Kerala, India and a Bachelor’s degree in Biotechnology, Microbiology, and Chemistry from Acharya Nagarjuna University, India. Pratap also holds a Postgraduate Diploma in Patent informatics from the Academy of Scientific and Innovative Research (AcSIR) at the CSIR Unit of Research and Development of Information Products (URDIP), India and worked as a Patent researcher in the same.

Plant viruses and horticultural crop improvement

Dr Dietzgen is internationally recognised for his work on plant virus characterisation, detection and engineered resistance. Before joining UQ, Dr Dietzgen was a Science Leader in Agri-Science in the Queensland Department of Employment, Economic Development and Innovation. He previously held research positions at the University of Adelaide, University of California, Cornell University and University of Kentucky. Dr Dietzgen’s research interests are in molecular virus-plant-insect interactions, virus biodiversity and evolution, and disease resistance mechanisms. His focus is on the biology of RNA viruses in the family Rhabdoviridae and the molecular protein interactions of plant-adapted rhabdoviruses and tospoviruses. He has published extensively on plant virus characterisation and genetic variability, RNAi- mediated virus resistance and diagnostic technologies with 20 review articles and book chapters and over 65 peer-reviewed publications.

Birgitta Ebert’s research focuses on developing biotechnology concepts to address critical challenges such as pollution, climate change and overexploitation of natural resources.

She specializes in improving microbial catalysts for eco-friendly chemical and material production by leveraging metabolic engineering, synthetic biology, systems analysis, and modelling. Her goal is to create microbial cell factories that convert renewable resources and waste into valuable products, reducing reliance on petrochemicals. She collaborates closely with chemists and chemical engineers to enhance the integration of chemical and biological processes for improved efficiency and sustainability.

Birgitta has a background in Chemical Engineering and a PhD in Systems Biotechnology from TU Dortmund University (Germany). She led a research group in Systems Metabolic Engineering at the Institute of Applied Microbiology at RWTH Aachen University (Germany) from 2012 to 2019. In 2016, she expanded her expertise in Synthetic Biology by joining the Keasling lab at the University of California in Berkeley and the Joint BioEnergy Institute in Emeryville (USA).

Since April 2019, she has been at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland, applying her expertise to engineer microbial cell factories for fermentation-based manufacturing.

Sebastian is an expert on molecular pharmacology of G protein-coupled receptors (GPCRs - the largest class of cell surface recpetors and major drug targets). His lab has a particular interest in those involved in communication between the gastrointestinal tract and brain (the so-called gut-brain axis). Current foccusses include ghrelin, melanocortin 4, dopamine D2, and cholecystokinin receptors and the lab has also worked on the calcitonin, glucagon-like peptide 1 and other receptors. His lab is interested in answering complelling biological questions relating to physiology and pathophysiology of the gut-brain axis all the way down to the level of the receptor.

Sebastian is from Adelaide and received his BSc(Hons) and PhD. from the University of Adelaide, where he worked on the Aryl Hydrocarbon receptor in the lab of Murray Whitelaw. He then did postdoctoral research on haematopoitic stem cell differentiation in Kelly McNagny’s lab at the Biomedical Research Centre at the University of British Columbia before joining Patrick Sexton to work on G protein-coupled receptors at Monash University .

Sebastian is now an ARC Future Fellow with his own research program in the School of Biomedical Sciences at the University of Queensland. He remains an adjunct member of MIPS DDB as well as CCeMMP.

Sebastian has honours and PhD positions for motivated students who have a strong desire to assume ownership of a project and work independently.

Frédéric Gachon received his PhD in 2001 from the University of Montpellier (France). Between 2001 and 2006, he performed his post-doctoral training with Prof. Ueli Schibler at the department of Molecular Biology of the University of Geneva (Switzerland), where he started to work on the regulation of physiology by the circadian clock. In 2006, he worked at the Institute of Human Genetic in Montpellier (France) as a junior group leader before continued his career in Switzerland as an Assistant Professor in the Department of Pharmacology of the University of Lausanne (2009-2012) and as a group leader at the Nestlé Institute of Health Sciences, Lausanne (2012-2018). He finally joined the Institute of Molecular Bioscience of the University of Queensland as an Associate Professor in 2019. During all these years, research of the Gachon group focussed on the understanding of the role of feeding and circadian rhythms on mouse and human physiology, contributing to the fundamental basis for chronopharmacology and chrononutrition.

The molecular evolution of cytochrome P450 Enzymes: biological catalysts of unprecedented versatility.

Cytochrome P450 enzymes (CYPs, P450s) especially those responsible for drug metabolism in humans, are the unifying theme of the research in our lab. These fascinating enzymes are catalysts of exceptional versatility, and functional diversity. In humans they are principally responsible for the clearance of a practically unlimited variety of chemicals from the body, but are also critical in many important physiological processes. In other organisms (plants, animals, bacteria, fungi, almost everything!) they carry out an unprecedented range of functions, such as defense, chemical communication, neural development and even pigmentation. P450s are involved in the biosynthesis of an unequalled range of potent, biologically active natural products in microbes, plants and animals, including many antibiotics, plant and animal hormones, signalling molecules, toxins, flavours and fragrances. We are studying how P450s have evolved to deal with novel substrates by reconstructing ancestral precursors and evolutionary pathways, to answer such questions as how did the koala evolve to live on eucalyptus leaves, a toxic diet for most mammals.

The capabilities of P450s are only just coming to be fully recognized and structural studies on P450s should yield critical insights into how enzyme structure determines function. For example, recently we discovered that P450s are present within cells in the Fe(II) form, a finding that has led to a radical revision of the dogma concerning the P450 catalytic cycle, and has implications for the control of uncoupling of P450 activity in cells. Importantly, the biotechnological potential of P450s remains yet to be exploited. All of the specific research themes detailed below take advantage of our recognized expertise in the expression of recombinant human cytochrome P450 enzymes in bacteria. Our group is interested in finding out how P450s work and how they can be made to work better.

Artificial evolution of P450s for drug development and bioremediation: a way of exploring the sequence space and catalytic potential of P450s. The demonstrated catalytic diversity of P450 enzymes makes them the ideal starting material for engineering sophisticated chemical reagents to catalyse difficult chemical transformations. We are using artificial (or directed) evolution to engineer enzymes that are more efficient, robust and specialized than naturally occurring enzymes with the aim of selecting for properties that are commercially useful in the areas of drug discovery and development and bioremediation of pollutants in the environment. The approach we are using also allows us to explore the essential sequence and structural features that underpin all ~12000 known P450s so as to determine how they work.

Synthetic biology of enzymes for clean, green, solar-powered chemistry in drug development, bioremediation and biosensors. We have identified ancestral enzymes that are extremely thermostable compared to their modern counterparts, making them potentially very useful in industry, since they can withstand long incubations at elevated temperatures. They can be used as ‘off the shelf’ reagents to catalyse useful chemistry, such as in in drug discovery and development, fine chemicals synthesis, and cleaning up the environment. Working with drug companies, we are exploring how they can be best deployed in chemical processes and what structural features make them efficient, robust and specialized. We are also immobilizing P450s in virus-like-particles as ‘designer’ reagents that can be recovered from reactions and reused. To make such processes cheaper and more sustainable, we are using photosynthesis to power P450 reactions for clean, green biocatalysis in microalgae.

Biosketch:

After graduating from UQ with first class Honours in Biochemistry, Elizabeth took up a Royal Commission for the Exhibition of 1851 Overseas Scholarship to pursue doctoral work at Oxford University then undertook postdoctoral work at the Center in Molecular Toxicology and Department of Biochemistry at Vanderbilt University School of Medicine with Prof. F.P. Guengerich. She returned to UQ in 1993 to take up a position in Pharmacology and joined the School of Chemistry and Molecular Biosciences in 2009 as a Professor of Biochemistry.